Results 141 to 150 of about 6,856 (183)

Antileishmanial activity in Israeli plants

Annals of Tropical Medicine & Parasitology, 2009
Leishmaniasis is a vector-borne disease caused by flagellated protozoan parasites of the genus Leishmania, which affects both humans and other mammals. Most of the available drugs against the disease are toxic and parasite resistance to some of the drugs has already developed.
El-On, J., Ozer, L., Gopas, J., Sneir, R., Enav, H. ; https://orcid.org/0000-0001-5470-1230, Luft, N., Davidov, G., Golan-Goldhirsh, A.   +7 more
openaire   +3 more sources

Antitrypanosomal and Antileishmanial Activities

2018
The so-called neglected tropical diseases, which are endemic in 149 tropical and subtropical countries, affect more than 1 billion people annually, including 875 million children in developing economies. These diseases are responsible for over 500,000 deaths per year and are characterized by long-term disability and severe pain.
Sanchez Alberti, Andrés, Cerny, Natacha, Bivona, Augusto Ernesto, Cazorla, Silvia Ines   +3 more
openaire   +2 more sources

Antileishmanial Patents Antileishmanial Current Drugs and Relevant Patents

Recent Patents on Anti-Infective Drug Discovery, 2011
The World Health Organization has classified the leishmaniasis as a major tropical disease. An effective vaccine is not available and the chemotherapy is the only effective way to treat all forms of disease. Currently, the therapy is toxic, expensive and the resistance has emerged as a serious problem, which has compelled the search for new ...
openaire   +2 more sources

Antileishmanial and antitrypanosomal drug identification

Emerging Topics in Life Sciences, 2017
Although the treatments for human African trypanosomiasis (HAT), leishmaniasis and Chagas disease (CD) still rely on drugs developed several decades ago, there has been significant progress in the identification, development and use of novel drugs and formulations. Notably, there are now two drugs in clinical trial for HAT, fexinidazole and acoziborole;
Simon L, Croft, Eric, Chatelain, Michael P, Barrett   +2 more
openaire   +2 more sources

Proteinase inhibitors as antileishmanial agents

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1982
Leishmania mexicana mexicana amastigote proteinase activity was largely inhibited by low concentrations of leupeptin, antipain and two epoxysuccinates, compounds known to affect cysteine proteinases. Of these inhibitors, only two had leishmanicidal activity. trans-Dicyclohexylepoxysuccinate at 10 microgram/ml inhibited the in vitro transformation of L.
G H, Coombs, D T, Hart, J, Capaldo
openaire   +2 more sources

Present status of antileishmanial vaccines

Molecular and Cellular Biochemistry, 2003
The term leishmaniasis refers collectively to various clinical syndromes that are caused by obligate intracellular protozoa of the genus Leishmania. Approximately 350 million people in 8 countries are estimated to be threatened by the disease. The World Health Organization estimated that there are 12 million cases of all forms of leishmaniasis ...
Monidipa, Ghosh, Santu, Bandyopadhyay
openaire   +2 more sources

Development of antileishmanial lipid nanocomplexes

Biochimie, 2014
Visceral leishmaniasis is a life-threatening disease that affects nearly a million people every year. The emergence of Leishmania strains resistant to existing drugs complicates its treatment. The purpose of this study was to develop a new lipid formulation based on nanocochleates combining two active drugs: Amphotericin B (AmB) and Miltefosine (HePC).
Pham, T.T.H., Gueutin, C., Cheron, M., Abreu, S., Chaminade, P., Loiseau, P.M., Barratt, G.   +6 more
openaire   +3 more sources

Potential of Doxorubicin as an Antileishmanial Agent

The Journal of Parasitology, 1992
Doxorubicin, a well characterized anticancer drug, was tested in vitro and in vivo for activity against Leishmania donovani. Activity in vitro was very high against both the promastigote and amastigote forms of this parasite with 50% effective dose (ED50) values on the order of 0.43 microM and 0.86 microM, respectively.
R, Sett, N, Basu, A K, Ghosh, P K, Das
openaire   +2 more sources

Azaterphenyl diamidines as antileishmanial agents

Bioorganic & Medicinal Chemistry Letters, 2008
Eighteen diamidino azaterphenyls and analogues were evaluated as anti-leishmanials; nine of the compounds gave IC50 values less than 1 microM, five exhibited values less than 0.40 microM, and two gave values less than 0.10 microM in a Leishmania donovani axenic amastigote assay.
Laixing, Hu, Reem K, Arafa, Mohamed A, Ismail, Tanja, Wenzler, Reto, Brun, Manoj, Munde, W David, Wilson, Sandra, Nzimiro, Serene, Samyesudhas, Karl A, Werbovetz, David W, Boykin   +10 more
openaire   +2 more sources

Synthesis and Antileishmanial Activity of α-Cyano Ethyl Propenoates - a New Class of Antileishmanials

Arzneimittelforschung, 2011
A number of alpha-cyano-beta-substituted ethyl propenoates were synthesised by condensation of appropriate aldehydes with ethyl cyanoacetate in basic medium. These compounds have been studied for their antileishmanial activities in vivo in hamsters. Two compounds exhibited 70-77% activities both by intramuscular and oral routes.
S, Tiwari, S, Gupta, R P, Tripathi, A R, Khan, J C, Katiyar, A P, Bhaduri   +5 more
openaire   +2 more sources